On March 13, DeepSeek's significant advancements in artificial intelligence garnered widespread attention from China's venture capital community, marking an end to a three-year downturn in the sector. According to Alex Zhavoronkov, founder and CEO of Insilico Medicine, DeepSeek unveiled a new product at the end of January this year that rivals OpenAI. Concurrently, its artificial intelligence-driven drug research and development company concluded a Series E funding round of US$110 million, led by Value Partners Group. This successful funding round was finalized last month.
